Polymer-drug conjugates as modulators of cellular apoptosis
- 1 June 2007
- journal article
- review article
- Published by Springer Nature in The AAPS Journal
- Vol. 9 (2), E200-E207
- https://doi.org/10.1208/aapsj0902022
Abstract
The successful clinical application of polymer-protein conjugates (PE Gylated enzymes and cytokines) and the promising results arising from clinical trials with polymerbound chemotherapy (eg, doxorubicin or paclitaxel) have established their potential to reduce toxicity and improve activity in chemotherapy-refractory patients. Furthermore, and more important, they have also provided a firm foundation for more sophisticated second-generation constructs that deliver the newly energing target-directed bioactive agents (eg, modulators of apoptosis, cell cycle, anti-angiogenic drugs) in addition to polymer-based drug combinations (eg, endocrine therapy and chemotherapy). This review will focus on polymer-drug conjugate modulators of cellular apoptosis to be used as single pro-poptotic (eg, cancer) or anti-apoptotic (eg, ischemia) agents or as a combination therapy.Keywords
This publication has 74 references indexed in Scilit:
- The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors; A reviewEuropean Journal Of Cancer, 2006
- Polymer genomics: An insight into pharmacology and toxicology of nanomedicines☆Advanced Drug Delivery Reviews, 2006
- Theoretical Basis, Experimental Design, and Computerized Simulation of Synergism and Antagonism in Drug Combination StudiesPharmacological Reviews, 2006
- Poly-l-glutamic acid (PGA) Aided Inhibitors of Apoptotic Protease Activating Factor 1 (Apaf-1): An Antiapoptotic Polymeric NanomedicineJournal of Medicinal Chemistry, 2006
- Successful Treatment With Novel Triple Drug Combination Consisting of Interferon-γ, Interferon Alfacon-1, and Ribavirin in a Nonresponder HCV Patient to Pegylated Interferon TherapyDigestive Diseases and Sciences, 2006
- Polymer-peptide conjugates for angiogenesis targeted tumor radiotherapyNuclear Medicine and Biology, 2006
- Apoptosis: mechanisms and relevance in cancerAnnals of Hematology, 2005
- Structure of the apoptotic protease-activating factor 1 bound to ADPNature, 2005
- Acquired and specific immunological mechanisms co-responsible for efficacy of polymer-bound drugsJournal of Controlled Release, 2002
- Mechanisms of anticancer action of HPMA copolymer-bound doxorubicinMacromolecular Symposia, 2001